checkAd

    BioLargo (BLGO) – environmental solutions provider (Seite 2)

    eröffnet am 26.08.20 22:10:08 von
    neuester Beitrag 09.10.22 17:31:09 von
    Beiträge: 126
    ID: 1.330.097
    Aufrufe heute: 0
    Gesamt: 3.918
    Aktive User: 0

    Werte aus der Branche Chemie

    WertpapierKursPerf. %
    3.280,00+10.833,33
    115,63+62,31
    43,01+22,89
    33,99+22,71
    1,0180+17,96
    WertpapierKursPerf. %
    2,9600-8,78
    31,60-9,71
    3,4650-10,70
    4,7143-13,82
    0,5600-16,91

    Beitrag zu dieser Diskussion schreiben

     Durchsuchen
    • 2
    • 13

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 31.05.22 19:45:03
      Beitrag Nr. 116 ()
      For BioLargo, Cleantech Isn't Just A Tagline
      May 31, 2022
      https://www.benzinga.com/markets/penny-stocks/22/05/27469025…
      Biolargo | 0,178 $
      Avatar
      schrieb am 23.05.22 17:22:43
      Beitrag Nr. 115 ()
      BioLargo, Inc. Discusses Record-Breaking Quarter on The Stock Day Podcast
      Newsfile Corp.

      Mon, May 23, 2022,
      https://feeds.issuerdirect.com/news-release.html?newsid=7951…

      Phoenix, Arizona--(Newsfile Corp. - May 23, 2022) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), a company that invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. President and CEO of BioLargo, Dennis P. Calvert, joined Stock Day host Sever Oakley for an interview on the Stock Day Podcast.

      Oakley began by asking about the company's background and vision. "BioLargo has over a decade of R&D behind it, and we've been inventing chemistries, technical solutions, and all sorts of innovations to help solve some of the biggest problems that face our planet, including clean air, clean water, and a cleaner Earth," explained Calvert. "All of that R&D is beginning to pay off through commercialization."

      Oakley then commented on the company's recently announced record-breaking quarter and asked about the drivers behind this success. "Most of this is organic growth, so it is a very exciting time," answered Calvert. "It was a 69% growth over last year's quarter," he added, noting that the company brought in nearly a million in revenue in the first quarter of 2022.

      The conversation then turned to the company's technology that treats water contaminated with per- and polyfluoroalkyl substances (PFAS). Calvert explained, "PFAS are 'forever chemicals' which have been used for about 35 years in all sorts of plastic coatings… PFAS has been linked to adverse health effects, including cancer." He added, "We have an innovation that we believe will be the number one technical solution for concentrating, extracting, and removing those contaminants from nature."

      "What is the status of your PFAS treatment technology division?" asked Oakley. "We've just completed some testing with one of the largest [municipal water agencies] in the world, and that data and proof of claim has become instrumental," said Calvert. "We achieved what is called a non-detect status, which means the level was so low that it was below the level of being detectable by current technology," he said, before elaborating on the company's growing list of prospects and channel partners, as well as a pipeline of potential projects.

      Oakley then turned the conversation to BioLargo's partnership with Garratt-Callahan, the largest privately owned water treatment company in North America. The two companies have partnered to bring a new wastewater treatment technology to market. "We have developed a system that has been validated, which we call the Minimum Liquid Discharge (MLD) [system]," said Calvert. "Garratt-Callahan asked us to design, make, and prove up this machine, and in exchange we would become the supply chain partner and they would manage distribution."

      Calvert discussed the plan for rolling out the MLD system with Garratt-Callahan customers, "We are in current negotiations with customers… It is about a year and a half of work coming to fruition on the commercial side and we're pretty excited about the next few steps."

      "Could you tell us about the new contract with the waste-to-energy conversion plant project in South America?" asked Oakley. Calvert explained that BioLargo has been contracted for the first phase of the project, a comprehensive project planning stage (i.e., "feasibility study"), and may be hired for additional stages with greater potential value. He finished by adding that if the project advances to completion, the total project cost could reach a half billion dollars over its lifetime of four or more years.

      To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8088354-biolargo-inc-discusses-r…
      Biolargo | 0,177 $
      Avatar
      schrieb am 18.05.22 10:52:30
      Beitrag Nr. 114 ()
      👍

      BioLargo's First Quarterly Report of 2022 Highlights: Record Company-wide Revenues, Subsidiaries Achieving and Approaching Profitability, and Progress of Key Growth Catalysts

      WESTMINSTER, CA / ACCESSWIRE / May 17, 2022 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Quarterly Report on Form 10-Q for the period ended March 31, 2022, with the SEC yesterday (www.biolargo.com/sec-filings). Here the company has provided highlights from the report as well as commentary on the company's strategy for growth.

      "BioLargo is at a turning point," said the company's President and CEO, Dennis P. Calvert. "After investing years and millions of dollars into R&D for our innovative technologies, in this quarter we generated record revenues, our subsidiary ONM Environmental turned an operating profit, and our engineering subsidiary ended the quarter just shy of profitability. Although we have solidified our reputation as a trusted and credible cleantech solutions provider thanks to our commitment to creating best-in-class sustainable technologies and our growing roster of talented engineers and scientists, we still must work hard to continue to achieve these results in the long term. Now we are capitalizing on these assets in a way we believe will create significant value for our company and stockholders."

      https://feeds.issuerdirect.com/news-release.html?newsid=8923…
      Biolargo | 0,212 $
      Avatar
      schrieb am 23.04.22 11:01:09
      Beitrag Nr. 113 ()
      BioLargo starting 1:08

      Bezinga
      4 ESG Stocks For Earth Day | All Access
      19 hrs ago


      Biolargo | 0,220 $
      Avatar
      schrieb am 21.04.22 22:56:35
      Beitrag Nr. 112 ()
      :)

      POOPH Times Square Billboard 15 Second Commercial

      https://vimeo.com/700511730
      Biolargo | 0,217 $

      Trading Spotlight

      Anzeige
      Nurexone Biologic
      0,4080EUR -1,92 %
      NurExone Biologic: Das sollten Sie nicht versäumen! mehr zur Aktie »
      Avatar
      schrieb am 20.04.22 18:19:08
      Beitrag Nr. 111 ()
      👍

      BioLargo Continues Growth Trend by Breaking Quarterly Revenue Record
      WESTMINSTER, CA / ACCESSWIRE
      April 20, 2022

      https://feeds.issuerdirect.com/news-release.html?newsid=5591…

      New company-wide quarterly revenue record
      BioLargo generated approximately $900,000 in revenue (company-wide) for the first quarter of 2022, representing an approximate 60% increase compared with the same period in 2021. Leading the way was subsidiary ONM Environmental with a new quarterly revenue record of approximately $550,000, and BioLargo's engineering subsidiary with quarterly revenue of approximately $350,000, while it continued to support R&D on the company's patented technologies. With these revenues, each of ONM Environmental and BioLargo Engineering moved closer to generating an operating profit. Note however, these preliminary revenue figures have not been reviewed, and are subject to change pending review by the company's independent registered public accounting firm; the company will include its full results of operations in its quarterly report, which it intends to file with the SEC on about May 16, 2022.

      Feasibility contract awarded for potential large waste-to-energy conversion plant project
      Randall Moore, President of BioLargo Engineering, Science & Technologies, said, "The development of this waste-to-energy conversion plant is directly in our wheelhouse of past experience and knowledge. To process two million tons of municipal solid waste per year, the total capital outlay by the developer for a processing plant of that size could exceed $500 million, with the potential to keep our team busy for the next four years."

      Dennis P. Calvert, President and CEO of BioLargo, commented, "We look forward to sharing additional information as this project advances. We are continuing our strategy of employing strategic partnerships to develop new revenue channels for our cleantech products and services. As we referenced in our recently published annual report, we have additional channel partnerships in various stages of negotiation for our PFAS treatment system and are eager to provide more information soon. When combined with our other partnerships aimed at delivering cleantech solutions, including with Garratt-Callahan and Ikigai, we believe these record revenues are the beginning of what we believe will be accelerated growth for our company."
      Biolargo | 0,230 $
      Avatar
      schrieb am 06.04.22 22:55:58
      Beitrag Nr. 110 ()
      Das wichtigste aus dem letzten Pooph Video...

      Ikigai partnership: BioLargo established a partnership with Ikigai Marketing Works, LLC to support the roll-out of a new pet odor control product based on BioLargo's proprietary technology, ultimately aimed at adoption by big-box retailers. Ikigai completed a test-marketing phase to assess the likelihood that the new brand would be a commercial success and subsequently made orders for product (manufactured by BioLargo) that exceed both partners' initial projections. BioLargo also earns a royalty on each bottle sold and would receive 20% of any eventual sale of the product line. Ikigai's sales are growing.



      Biolargo | 0,238 $
      Avatar
      schrieb am 06.04.22 18:01:53
      Beitrag Nr. 109 ()
      👍💲💲💲

      Biolargo | 0,232 $
      Avatar
      schrieb am 31.03.22 18:31:27
      Beitrag Nr. 108 ()
      👍

      "We expect to make a big splash in the immediate future with our Aqueous Electrostatic Concentrator (AEC) PFAS treatment system, including with new channel partnerships, and we soon expect to secure our first commercial accounts with our Advanced Oxidation System (AOS) energy-efficient water treatment technology.""


      BioLargo Annual Report for 2021 Highlights Active Commercial Catalysts, Expanding Partnerships, and Improved Balance Sheet

      March 31, 2022
      https://feeds.issuerdirect.com/news-release.html?newsid=8703…
      Biolargo | 0,241 $
      Avatar
      schrieb am 21.03.22 21:54:11
      Beitrag Nr. 107 ()
      As Pet Ownership In U.S. Skyrockets, Two Companies Join Forces To Say "Pooph" To Household Odor
      March 21, 2022
      https://www.benzinga.com/markets/penny-stocks/22/03/26215609…

      Ikigai Marketing Works, LLC is composed of consumer product marketing executives with experience launching and growing multiple blockbuster consumer products including Oxiclean, Flawless, and Copperfit. Ikigai was responsible for developing the Pooph™ brand and produced new television commercials and other advertising content to help boost the brand. The company recently conducted a television direct-response test marketing campaign to assess the Pooph™ probability of being a commercial success.

      BioLargo CEO Dennis Calvert said, "We manufacture the PoophTM product for Ikigai and we receive a royalty on sales and 20% of any eventual exit. Ikigai will finance and manage product rollout, distribution, and marketing. We are excited about the potential to create significant new revenue for both parties.”
      Biolargo | 0,239 $
      • 2
      • 13
       DurchsuchenBeitrag schreiben


      Investoren beobachten auch:

      WertpapierPerf. %
      0,00
      0,00
      -0,89
      -1,22
      +7,08
      -1,52
      -0,32
      -2,21
      -0,47
      -6,80
      BioLargo (BLGO) – environmental solutions provider